Critical

Acute promyelocytic leukaemia with coagulopathy

APL / DIC · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A subtype of acute myeloid leukaemia presenting with life-threatening bleeding from DIC and hyperfibrinolysis. Early ATRA (all-trans retinoic acid) and aggressive blood-product support before genetic confirmation are life-saving.

Assessment

Investigations

  • FBC + blood film (promyelocytes)
  • Coagulation, fibrinogen, D-dimer (DIC)
  • Urgent haematology and PML-RARA testing

Management

  • Start ATRA urgently on clinical suspicion - do not wait for confirmation
  • Aggressive product support: platelets, fibrinogen/cryoprecipitate, FFP
  • Maintain fibrinogen and platelet targets
  • Watch for differentiation (ATRA) syndrome
  • Haematology; transfer to a treatment centre

Drugs & doses

ATRA (all-trans retinoic acid)
Platelets / cryoprecipitate / FFP

Disposition

Haematology centre.

Suspected APL with bleeding is an emergency - give ATRA and clot factors early, before molecular results return.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.